A citation-based method for searching scientific literature

Darrell R Borger, Kenneth K Tanabe, Kenneth C Fan, Hector U Lopez, Valeria R Fantin, Kimberly S Straley, David P Schenkein, Aram F Hezel, Marek Ancukiewicz, Hannah M Liebman, Eunice L Kwak, Jeffrey W Clark, David P Ryan, Vikram Deshpande, Dora Dias-Santagata, Leif W Ellisen, Andrew X Zhu, A John Iafrate. Oncologist 2012
Times Cited: 497







List of co-cited articles
1221 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
34

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
33

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira,[...]. N Engl J Med 2010
32

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020
275
30

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011
29

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
M Fernanda Amary, Krisztian Bacsi, Francesca Maggiani, Stephen Damato, Dina Halai, Fitim Berisha, Robin Pollock, Paul O'Donnell, Anita Grigoriadis, Tim Diss,[...]. J Pathol 2011
622
29

Genomic spectra of biliary tract cancer.
Hiromi Nakamura, Yasuhito Arai, Yasushi Totoki, Tomoki Shirota, Asmaa Elzawahry, Mamoru Kato, Natsuko Hama, Fumie Hosoda, Tomoko Urushidate, Shoko Ohashi,[...]. Nat Genet 2015
608
25

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
25

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
P Wang, Q Dong, C Zhang, P-F Kuan, Y Liu, W R Jeck, J B Andersen, W Jiang, G L Savich, T-X Tan,[...]. Oncogene 2013
262
22

Recurring mutations found by sequencing an acute myeloid leukemia genome.
Elaine R Mardis, Li Ding, David J Dooling, David E Larson, Michael D McLellan, Ken Chen, Daniel C Koboldt, Robert S Fulton, Kim D Delehaunty, Sean D McGrath,[...]. N Engl J Med 2009
21

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Jeffrey S Ross, Kai Wang, Laurie Gay, Rami Al-Rohil, Janne V Rand, David M Jones, Hwa J Lee, Christine E Sheehan, Geoff A Otto, Gary Palmer,[...]. Oncologist 2014
285
20

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Jesus M Banales, Vincenzo Cardinale, Guido Carpino, Marco Marzioni, Jesper B Andersen, Pietro Invernizzi, Guro E Lind, Trine Folseraas, Stuart J Forbes, Laura Fouassier,[...]. Nat Rev Gastroenterol Hepatol 2016
603
19

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward, Jay Patel, David R Wise, Omar Abdel-Wahab, Bryson D Bennett, Hilary A Coller, Justin R Cross, Valeria R Fantin, Cyrus V Hedvat, Alexander E Perl,[...]. Cancer Cell 2010
19

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
19

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
413
19

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Benjamin R Kipp, Jesse S Voss, Sarah E Kerr, Emily G Barr Fritcher, Rondell P Graham, Lizhi Zhang, W Edward Highsmith, Jun Zhang, Lewis R Roberts, Gregory J Gores,[...]. Hum Pathol 2012
157
18

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Rondell P Graham, Emily G Barr Fritcher, Ekaterina Pestova, John Schulz, Leonid A Sitailo, George Vasmatzis, Stephen J Murphy, Robert R McWilliams, Steven N Hart, Kevin C Halling,[...]. Hum Pathol 2014
170
18

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Yasuhito Arai, Yasushi Totoki, Fumie Hosoda, Tomoki Shirota, Natsuko Hama, Hiromi Nakamura, Hidenori Ojima, Koh Furuta, Kazuaki Shimada, Takuji Okusaka,[...]. Hepatology 2014
289
18

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Milind Javle, Maeve Lowery, Rachna T Shroff, Karl Heinz Weiss, Christoph Springfeld, Mitesh J Borad, Ramesh K Ramanathan, Lipika Goyal, Saeed Sadeghi, Teresa Macarulla,[...]. J Clin Oncol 2018
323
18

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng,[...]. Cancer Discov 2017
378
17

Cholangiocarcinoma.
Nataliya Razumilava, Gregory J Gores. Lancet 2014
971
17

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Ronan Swords, Robert H Collins, Gabriel N Mannis, Daniel A Pollyea,[...]. N Engl J Med 2018
691
17

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
Rasheduzzaman Chowdhury, Kar Kheng Yeoh, Ya-Min Tian, Lars Hillringhaus, Eleanor A Bagg, Nathan R Rose, Ivanhoe K H Leung, Xuan S Li, Esther C Y Woon, Ming Yang,[...]. EMBO Rep 2011
670
17

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Chaitanya R Churi, Rachna Shroff, Ying Wang, Asif Rashid, HyunSeon C Kang, Jacqueline Weatherly, Mingxin Zuo, Ralph Zinner, David Hong, Funda Meric-Bernstam,[...]. PLoS One 2014
273
16

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Farshad Farshidfar, Siyuan Zheng, Marie-Claude Gingras, Yulia Newton, Juliann Shih, A Gordon Robertson, Toshinori Hinoue, Katherine A Hoadley, Ewan A Gibb, Jason Roszik,[...]. Cell Rep 2017
245
16

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.
Yuchen Jiao, Timothy M Pawlik, Robert A Anders, Florin M Selaru, Mirte M Streppel, Donald J Lucas, Noushin Niknafs, Violeta Beleva Guthrie, Anirban Maitra, Pedram Argani,[...]. Nat Genet 2013
452
16

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, Amir T Fathi, Gail J Roboz, Jessica K Altman, Richard M Stone, Daniel J DeAngelo, Ross L Levine, Ian W Flinn,[...]. Blood 2017
788
15

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
Katharine Yen, Jeremy Travins, Fang Wang, Muriel D David, Erin Artin, Kimberly Straley, Anil Padyana, Stefan Gross, Byron DeLaBarre, Erica Tobin,[...]. Cancer Discov 2017
237
15

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
Supriya K Saha, Christine A Parachoniak, Krishna S Ghanta, Julien Fitamant, Kenneth N Ross, Mortada S Najem, Sushma Gurumurthy, Esra A Akbay, Daniela Sia, Helena Cornella,[...]. Nature 2014
271
15

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, Sevin Turcan, Christian Grommes, Carl Campos, Jennifer Tsoi, Owen Clark, Barbara Oldrini, Evangelia Komisopoulou,[...]. Science 2013
794
14

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Maeve A Lowery, Ryan Ptashkin, Emmet Jordan, Michael F Berger, Ahmet Zehir, Marinela Capanu, Nancy E Kemeny, Eileen M O'Reilly, Imane El-Dika, William R Jarnagin,[...]. Clin Cancer Res 2018
183
14

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Lipika Goyal, Aparna Govindan, Rahul A Sheth, Valentina Nardi, Lawrence S Blaszkowsky, Jason E Faris, Jeffrey W Clark, David P Ryan, Eunice L Kwak, Jill N Allen,[...]. Oncologist 2015
80
17

Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Jesus M Banales, Jose J G Marin, Angela Lamarca, Pedro M Rodrigues, Shahid A Khan, Lewis R Roberts, Vincenzo Cardinale, Guido Carpino, Jesper B Andersen, Chiara Braconi,[...]. Nat Rev Gastroenterol Hepatol 2020
441
14

New Horizons for Precision Medicine in Biliary Tract Cancers.
Juan W Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X Zhu. Cancer Discov 2017
251
13

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Parker L Sulkowski, Christopher D Corso, Nathaniel D Robinson, Susan E Scanlon, Karin R Purshouse, Hanwen Bai, Yanfeng Liu, Ranjini K Sundaram, Denise C Hegan, Nathan R Fons,[...]. Sci Transl Med 2017
286
13

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S Ward, Jay Patel, Alan Shih, Yushan Li, Neha Bhagwat, Aparna Vasanthakumar, Hugo F Fernandez,[...]. Cancer Cell 2010
13

Cholangiocarcinoma - evolving concepts and therapeutic strategies.
Sumera Rizvi, Shahid A Khan, Christopher L Hallemeier, Robin K Kelley, Gregory J Gores. Nat Rev Clin Oncol 2018
585
13

Identification of targetable FGFR gene fusions in diverse cancers.
Yi-Mi Wu, Fengyun Su, Shanker Kalyana-Sundaram, Nickolay Khazanov, Bushra Ateeq, Xuhong Cao, Robert J Lonigro, Pankaj Vats, Rui Wang, Su-Fang Lin,[...]. Cancer Discov 2013
478
13

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
Daniela Sia, Yujin Hoshida, Augusto Villanueva, Sasan Roayaie, Joana Ferrer, Barbara Tabak, Judit Peix, Manel Sole, Victoria Tovar, Clara Alsinet,[...]. Gastroenterology 2013
311
13

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.
John Bridgewater, Peter R Galle, Shahid A Khan, Josep M Llovet, Joong-Won Park, Tushar Patel, Timothy M Pawlik, Gregory J Gores. J Hepatol 2014
763
13

Biliary cancer: Utility of next-generation sequencing for clinical management.
Milind Javle, Tanios Bekaii-Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C Kang, Daniel Catenacci, Siraj Ali, Sunil Krishnan,[...]. Cancer 2016
175
13


Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Janeta Popovici-Muller, René M Lemieux, Erin Artin, Jeffrey O Saunders, Francesco G Salituro, Jeremy Travins, Giovanni Cianchetta, Zhenwei Cai, Ding Zhou, Dawei Cui,[...]. ACS Med Chem Lett 2018
168
12

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann, Jochen Meyer, Jörg Balss, David Capper, Wolf Mueller, Arne Christians, Jörg Felsberg, Marietta Wolter, Christian Mawrin, Wolfgang Wick,[...]. Acta Neuropathol 2009
801
12

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Peter Paschka, Richard F Schlenk, Verena I Gaidzik, Marianne Habdank, Jan Krönke, Lars Bullinger, Daniela Späth, Sabine Kayser, Manuela Zucknick, Katharina Götze,[...]. J Clin Oncol 2010
579
12

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Maeve A Lowery, Howard A Burris, Filip Janku, Rachna T Shroff, James M Cleary, Nilofer S Azad, Lipika Goyal, Elizabeth A Maher, Lia Gore, Antoine Hollebecque,[...]. Lancet Gastroenterol Hepatol 2019
94
12

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Lukas Bunse, Stefan Pusch, Theresa Bunse, Felix Sahm, Khwab Sanghvi, Mirco Friedrich, Dalia Alansary, Jana K Sonner, Edward Green, Katrin Deumelandt,[...]. Nat Med 2018
193
11

Exome sequencing of liver fluke-associated cholangiocarcinoma.
Choon Kiat Ong, Chutima Subimerb, Chawalit Pairojkul, Sopit Wongkham, Ioana Cutcutache, Willie Yu, John R McPherson, George E Allen, Cedric Chuan Young Ng, Bernice Huimin Wong,[...]. Nat Genet 2012
343
11

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, Christian Cotsoglou, William P Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi Braiteh,[...]. Br J Cancer 2019
164
11

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J W Valle, I Borbath, S A Khan, F Huguet, T Gruenberger, D Arnold. Ann Oncol 2016
305
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.